We’re excited to announce that Berkeley Lights and IsoPlexis are moving forward together as PhenomeX, a premier functional cell biology company. Visit Site

Improving Adoptive Cell Transfer: New Combinations for Greater Efficacy

In a paper published in Nature Communications, Parisi et al. from the University of California described how the novel agonist NKTR-214 outperforms IL-2 for improving ACT anti-tumor efficacy, identifying specific biomarkers that corresponded to increased response using IsoPlexis’ functional proteomics-based cellular characterization.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

A next-generation agonist for improving persistence and limiting tumor growth
Full cellular characterization of immune cells
NKTR-214 dramatically increases T cell polyfunctionality, a correlate to persistence
A Deeper Look

More about this

Improving Persistence and Limiting Tumor Growth

Adoptive cell transfer (ACT) is a promising therapeutic approach in the fight against cancer.

Conventionally in this therapy, patients receive tumor-infiltrating lymphocytes (TILs) or T cell receptor (TCR)-engineered blood T cells, along with high doses of interleukin-2 (IL-2) to support the expansion and function of the transferred cells.

However, IL-2-induced toxicity and immunosuppression pose problems for patients, limiting the clinical use of ACT. Parisi et al. utilized IsoPlexis’ functional proteomics-based cellular characterization to overcome these challenges.

Download this Paper Summary to learn more!

Get the